Skip to main content

Advertisement

Table 1 Patients and treatment characteristics

From: ECMO-treatment in patients with acute lung failure, cardiogenic, and septic shock: mortality and ECMO-learning curve over a 6-year period

  RF, n = 54 CS, n = 58 SS, n = 19 p value
Age, years 62 (53–70) 67 (55–73) 62 (55–73) 0.28
Weigh, kga 76.5 (64–102) 88 (70–99) 89.5 (77–102) 0.33
Male 29 (54) 37 (64) 14 (74) 0.26
SOFAb 6 (3–9) 10 (8–11) 8 (6–12) < 0.01
SAPS IIc 40 (31–60) 67 (48–78) 42 (32–61) < 0.01
Comorbidities
 -Art. hypertension 33 (61) 34 (60) 8 (42) 0.33
 -Coronary disease 7 (13) 40 (70) 4 (21) < 0.01
 -Diabetes mellitus 11 (20) 16 (28) 2 (11) 0.26
 -Hyperlipidaemia 4 (7) 8 (14) 5 (26) 0.11
 -Kidney injury 7 (13) 2 (4) 1 (5) 0.16
 -COPD 26 (48) 3 (5) 4 (21) < 0.01
Duration of hospitalisation, days 27 (15–40) 10 (4–36) 26 (18–67) < 0.01
Duration of ICU stay, days 20 (8–31) 7 (3–25) 20 (17–65) < 0.01
Time on ECMO support, days 12 (5–19) 5 (3–8) 14 (9–25) < 0.01
CPR pre-ECMO 3 (6) 38 (66) 3 (16) <  0.01
Mechanical ventilation time, h 391 (122–687) 129 (42–413) 423 (304–772) < 0.01
Renal replacement therapy 36 (67) 45 (78) 18 (95) < 0.05
Tracheotomy 33 (61) 20 (34) 17 (89) <  0.01
Weaning from ECMO 35 (65) 30 (52) 10 (53) 0.34
Death 29 (54) 34 (59) 11 (58) 0.86
ECMO-treatment before 2014 27 (50) 17 (29) 1 (5) < 0.01
  1. Data is given as median (interquartile range) and n(%)
  2. RF, respiratory failure; CS, cardiogenic shock; SS, septic shock; SOFA, Sequential Organ Failure Assessment; SAPS II, Simplified Acute Physiology Score; COPD, chronic obstructive lung disease; CPR, cardiopulmonary resuscitation
  3. a(n = 48 in RF, n = 46 in CS)
  4. b(n = 50 in RF, n = 56 in CS)
  5. c(n = 51 in RF, n = 56 in CS)